Cardiol Therapeutics Inc.: Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options Cardiol Therapeutics Inc. ( Cardiol" or the " Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has submitted an application to uplist the Company's common shares on The Nasdaq Capital Market ® (the " Nasdaq") and that it has received proceeds of over $10 million from the exercise of warrants and stock options. "The Nasdaq is the premier stock exchange for biotechnology companies, and we believe that this is an opportune time for Cardiol to formally apply for an uplisting of our common shares. We believe a Nasdaq listing will provide an ideal platform on which to build a leadership position in the treatment of inflammatory heart disease while elevating the Company's profile within the investment community," stated David Elsley, President and CEO of Cardiol Therapeutics.